Find Funding Opportunities

-Purpose. The purpose of this funding opportunity is to support research on: 1)causal factors explaining the current patterns observed in the careers of women in biomedical and behavioral science and engineering and variation across different subgroups and 2) the efficacy of programs designed to support the careers of women in these disciplines. Causal factors include individual characteristics, family and economic circumstances, disciplinary culture or practices, and features of the broader social and cultural context. Research on variation among underrepresented minority women and socioeconomically disadvantaged women is encouraged. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. The NIH intends to commit a total of approximately $3 million to this initiative and anticipates making 6 to 8 awards through this announcement. Direct costs are limited to $250,000 per year for a four (4) year period.

-Purpose. The purpose of the Neurological Academic Development Award (K12) is to facilitate and support the career development of pediatric neurologists who have made a commitment to independent research careers. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the Mentored Clinical Scientist Development Institutional Program Award (K12) mechanism. The NINDS K12 program provides support for up to three years of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators. -Funds Available and Anticipated Number of Awards. The total amount awarded and the number of awards will depend upon the funds available and the quality, duration, and costs of the applications received.

-The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented. Although the administrative supplements supported under this program provide funding for less than one percent of all individuals involved in NIH supported research, the NIH has found these awards to be an effective means of encouraging institutions to recruit from currently underrepresented groups. Administrative supplements must support work within the scope of the original project. -All NIH Institutes and Centers (ICs), the NIH Common Fund, and the National Institute for Occupational Safety (NIOSH, CDC) participate in this program. Candidates eligible for support under this supplement program include individuals at various career levels who come from groups that have been shown to be underrepresented in science. Such candidates include individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds. Detailed eligibility criteria are described in the full announcement.

The Office of Research on Womens Health (ORWH), participating Institutes and Centers (ICs) of the National Institutes of Health (NIH), and the Office of Dietary Supplements (ODS) announce a continuing program for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after a qualifying interruption for family or other responsibilities. For a comprehensive listing of qualifying interruptions, see Section III.1.B.

-Purpose. This funding opportunity announcement (FOA) is for projects from individual-investigators or small groups to collaborate with the NIH Roadmap for Medical Research National Centers for Biomedical Computing (NCBCs). For a description of the NCBCs see http://www.bisti.nih.gov/ncbc/.The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones.This FOA is intended to support exploratory biomedical informatics and computational biology researchapplications should be innovative, with high risk/high impact in new areas that are lacking preliminary data or development.Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism.For example, long-term projects, or projects designed to increase knowledge in a well-established area will not be considered for R21 awards. -Mechanism of Support This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PAR-08-184, that solicits applications under the R01 mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

-Purpose. This funding opportunity announcement (FOA) is for projects from individual-investigators or small groups to collaborate with the NIH Roadmap for Medical Research National Centers for Biomedical Computing (NCBCs). For a description of the NCBCs see http://www.bisti.nih.gov/ncbc/.The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-08-183 that solicits applications under the R21 mechanism, and which solicits innovative, high risk/high impact new areas that are lacking preliminary data or development. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

-Purpose. The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite research grant applications aimed at developing and or refinement of animal or ex vivo cell culture model systems for study of the neurologic complications of AIDS, with or without a history of drug or alcohol use. Recent advances in the development of the SIV model system highlight the power of animal model systems for study of the mechanisms underlying the pathology associated with lentiviral infection in the nervous system. These models will be key for developing therapeutic approaches for the treatment of patients suffering from NeuroAIDS and for understanding the basic biology of infection with HIV/AIDS. -Mechanism of Support.This funding opportunity will use the NIH Research Project (R01) award mechanism, and runs in parallel with a FOA of identical scientific scope, PAS-08-179, that encourages applications under the NIH Exploratory/Developmental (R21) grant award mechanism. For research projects with limited scope to develop animal or ex vivo models, applicants may submit their application in response to the NIH Small Research Grant Program (R03): http://grants.nih.gov/grants/guide/pa-files/PA-06-180.html -Funds Available and Anticipated Number of Awards. NINDS intends to commit a total of up to $1,500,000 in total costs over three years for payment of applications responsive to this FOA and the companion FOA (see above). NIDA and NIMH intend to contribute an additional $500,000 and $400,000 each year, respectively, to these FOAs. NIAAA is not setting aside any specific funds for these FOAs; funding determination will depend on the overall scientific merit of the applications and the availability of funds.

-Purpose. The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite research grant applications aimed at developing and or refinement of animal or ex vivo cell culture model systems for study of the neurologic complications of AIDS, with or without a history of drug or alcohol use. Recent advances in the development of the SIV model system highlight the power of animal model systems for study of the mechanisms underlying the pathology associated with lentiviral infection in the nervous system. These models will be key for developing therapeutic approaches for the treatment of patients suffering from NeuroAIDS and for understanding the basic biology of infection with HIV/AIDS. -Mechanism of Support. This funding opportunity will use the NIH Research Project (R21) award mechanism, and runs in parallel with a FOA of identical scientific scope, PAS-08-178, that encourages applications under the NIH Research Project Grant (R01) award mechanism. For research projects with limited scope to develop animal or ex vivo models, applicants may submit their application in response to the NIH Small Research Grant Program (R03): http://grants.nih.gov/grants/guide/pa-files/PA-06-180.html

This research training program is designed to build research capacity in low- and middle-income countries (LMICs) in the fields related to cancer, cerebrovascular disease including stroke, lung disease including chronic obstructive pulmonary disease (COPD) and environmental factors including indoor air pollution, and obesity and lifestyle factors related to these conditions as well as genetics of non-communicable diseases. The institutions applying can be domestic or foreign, but have to exhibit the ability to do such training, and must exhibit that they have existing research programs in these fields.

Purpose. The purpose of this open competition Funding Opportunity Announcement (FOA) is to stimulate the translation of innovative therapies suitable for children with brain tumors from the laboratory to early phase clinical testing. To achieve this goal, the National Cancer Institute (NCI) intends to continue a Pediatric Brain Tumor Consortium (PBTC) program. The NCI will support one multi-center clinical trials group (a Consortium) that will be responsible for timely conduct of the Phase 1, Phase 2, and pilot studies evaluating novel treatment approaches relevant to the pediatric brain tumor population. The National Institute of Neurological Disorders and Stroke (NINDS), is co-sponsoring this initiative because of a shared interest with NCI in the treatment of pediatric brain tumors. NINDS will be involved in coordinating PBTC activities across other NIH-supported normal and disease-oriented brain imaging Networks (including the NCI-supported adult brain tumor consortium) as well as in aspects related to the neurocognitive, quality-of-life impact of certain treatments on long-term survivors of pediatric brain tumors. Each application submitted in response to this FOA must include plans for (i) the PBTC Operations and Statistics/Data Centers and (ii) up to seven member institutions. The proposed PBTC must be able to (i) conduct Phase 1, Phase 2, and pilot clinical trials of novel treatment approaches for children with brain tumors, focusing whenever appropriate on clinical trials that require the specialized abilities of the PBTC collaborating experienced neurosurgeons, neuro-oncologists, radiation oncologists and neuroimagers; and (ii) conduct and/or support laboratory studies related to PBTC clinical trials that may provide information relevant to the success or failure of therapy.